Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
June 16, 2024 06:10 ET
|
Regeneron Pharmaceuticals, Inc.
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71% overall response rate, as presented in an EHA oral presentation and simultaneously...
2024 Urology Care Foundation Research Scholar Awardees Announced
June 14, 2024 15:13 ET
|
American Urological Association and Urology Care Foundation
BALTIMORE, June 14, 2024 (GLOBE NEWSWIRE) -- The American Urological Association (AUA) and the Urology Care Foundation, the official foundation of the AUA, are pleased to recognize 15 researchers as...
Renovaro, Inc. Announces $10 million in Equity Committed
June 14, 2024 09:06 ET
|
Renovaro Inc
Renovaro Announces $10m in Equity Committed
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
June 14, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
PatchMD Releases Medical Weight Loss Resources with Expert-Reviewed Articles on GLP-1 Agonists
June 14, 2024 09:00 ET
|
PatchMD
Las Vegas, NV, June 14, 2024 (GLOBE NEWSWIRE) -- PatchMD, a leader in innovative vitamin supplement delivery, is excited to announce the release of a series of comprehensive resources designed to...
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
June 14, 2024 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific...
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
June 14, 2024 07:30 ET
|
Cogent Biosciences, Inc.
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains...
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
Tilray Beverages Announces Campaign to Raise Awareness for Men’s Health
June 14, 2024 07:00 ET
|
Tilray Brands, Inc.
With this campaign and the partnerships involved, Tilray hopes to encourage more men to take an active role in their health and well-being.
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients
June 14, 2024 06:00 ET
|
Shattuck Labs, Inc.
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall...